Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC

NCT06861777 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

474

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

OTHER: Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy
OTHER: chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin
OTHER: TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)]
OTHER: Chemoradiotherapy

Sponsor

YIN LI